Introduction
============

Important advances in solid organ transplantation have led to improved patient survival over recent decades. With prolonged survival, the long-term complications of immunosuppressive therapy have become increasingly important. Decreased immune surveillance after transplant leads to a three- to fourfold increased risk of malignancy compared to the general population \[[@B1],[@B2]\].

Skin cancer is the most common form of post-transplant malignancy, particularly squamous cell carcinoma (relative risk 14 to 82) \[[@B3]-[@B6]\]. Although the incidence of melanoma is increased to a lesser degree than for squamous cell carcinoma, the potential for melanoma metastasis can introduce significant morbidity and mortality. Previous studies of melanoma in the transplant population have often had low numbers of cases, which precludes precise estimation of relative risk and produces variable estimates across studies. In addition, data on clinical outcomes such as metastasis or mortality are scarce for melanoma arising pre- and post-transplantation.

With its increased incidence and significant metastatic potential, melanoma has important implications for the care of transplant recipients. We aim to systematically review the published literature to determine the overall relative risk and prognosis of melanoma in solid organ transplant recipients.

Materials and methods
=====================

On 12 January 2012, electronic literature searches were conducted in Ovid MEDLINE (1946 to week 1 of January 2012, and In-Process and Other Non-Indexed Citations from 1946 to the present) and EMBASE (1980 to week 2 of 2012) to identify eligible studies using a comprehensive search strategy developed in consultation with an information specialist. The search terms consisted of the following: cancer/neoplas\*/tumor/tumour/malignan\*/carcin\*, or melanoma (expanded), and transplant (organ/kidney/renal/heart/cardiac/liver/hepat/lung/pulmonary/pancreas/intestine/spleen) and cohort/incidence/prevalence/prognosis.

Studies were limited to those published after 1995 in English and French. We included studies that estimated the relative risk or reported clinical outcomes (stage, recurrence, metastasis or death) of melanoma in a population-based inception cohort of solid organ transplant recipients (kidney, liver, heart, lung, pancreas or intestine). Studies were not excluded based on a quality assessment.

We initially screened all titles and abstracts to exclude articles that were clearly ineligible. We then reviewed full-text articles for all remaining citations. Reference lists from relevant articles were also reviewed for relevant articles. When needed, we obtained additional data from the study authors by email correspondence. If there were studies with more than a 50% overlap in their patient populations (based on country, year of transplant, type of graft and data source), we included data from only the most recent or inclusive study.

We pre-specified three main systematic review outcomes: the incidence and relative risk of melanoma diagnosed after solid organ transplantation compared to the general population; the outcomes of melanoma diagnosed after solid organ transplantation (post-transplant melanoma), including recurrence, metastasis and mortality (overall and melanoma-specific); and the outcomes of melanoma diagnosed prior to transplantation (pre-transplant melanoma).

For articles reporting incidence data, the pooled standardized incidence ratio (SIR) and 95% confidence interval (CI) were calculated using weights from a random effects model. The variation in effect sizes attributable to heterogeneity was quantified using the I-squared statistic. To explore potential sources of heterogeneity, we used meta-regression to adjust for the graft organ type (renal/liver versus heart/lung) and the most recent year of transplantation included in the study cohort (\>2000 versus ≤2000). All statistical analyses were performed using Stata 12.1.

Results
=======

The literature search identified 4,093 citations from Ovid MEDLINE and 6,311 from EMBASE. After removing duplicates, 7,512 unique citations were identified. We eliminated 7,369 citations based on title or abstract. A full-text review of the remaining 143 articles led to the further exclusion of 125 articles, most commonly because the studies were not population-based (Figure  [1](#F1){ref-type="fig"}).
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We identified 17 studies that reported the incidence of melanoma in a population-based cohort of solid organ transplant recipients \[[@B3]-[@B19]\]. No eligible studies of post-transplant melanoma outcomes were found. One population-based study reported the outcomes of pre-transplant melanoma. We requested and obtained additional information from the primary author for two studies through email correspondence \[[@B12],[@B20]\]. (Y Jiang, MD, 7 March 2011, and J Brewer, MD, 24 February 2012).

Incidence of post-transplant melanoma
-------------------------------------

Among the 17 population-based studies reporting melanoma incidence after transplant, five were excluded to avoid double counting of data that overlapped significantly with other studies \[[@B11],[@B14],[@B15],[@B17],[@B18]\]. Two Swedish studies collected data from the Swedish National In-patient Registry for patients transplanted between 1970 and 1994 \[[@B14]\] and between 1970 and 1997 \[[@B6]\]; we excluded the older cohort. A Norwegian study that reported skin cancer incidence in heart and renal transplant recipients \[[@B15]\] was excluded due to significant overlap with a larger study \[[@B10]\] that reported cancer risk after renal transplantation in all Nordic countries. We excluded two Australian \[[@B17],[@B18]\] studies that overlapped with a more recent study of a larger cohort of renal transplant recipients in Australia and New Zealand \[[@B7]\]. Finally, two studies from the United States used overlapping datasets; we included the more recent and inclusive study \[[@B11],[@B19]\].

Characteristics of the 12 included studies are listed in Table  [1](#T1){ref-type="table"}. The study populations were for kidney (*N* = 5), liver (*N* = 2), heart (*N* = 1) and various solid organ transplants (*N* = 4) performed in North America, Europe, Australia and New Zealand. There was less than 50% overlap of populations in three included studies from Sweden \[[@B6]\], Denmark \[[@B5]\] and the Nordic countries \[[@B10]\].

###### 

Characteristics of 12 included studies reporting relative incidence of post-transplant melanoma

  **First author (publication year)**   **Country**              **Graft type**              **Transplant years**   **Population size**   **Follow-up time**
  ------------------------------------- ------------------------ --------------------------- ---------------------- --------------------- ----------------------------------------
  Jiang \[[@B8]\]                       Canada                   Heart                       1981--1998             1,703                 10,369 person-years
  Webster \[[@B7]\]                     Australia, New Zealand   Renal                       1963--2004             15,183                130,186 person-years; median 7.2 years
  Birkeland \[[@B10]\]                  Nordic^a^                Renal                       1964--1982             5,692                 32,392 person-years
  Villeneuve \[[@B16]\]                 Canada                   Renal                       1981--1998             11,033                81,237 person-years
  Moloney \[[@B3]\]                     Ireland                  Renal                       1986--2001             1,558                 Median 5.7 years
  Bastiaannet \[[@B9]\]                 Netherlands              Renal                       1989--2003             1,125                 8165 person-years; mean 7.3 years
  Aberg \[[@B13]\]                      Finland                  Liver                       1982--2005             540                   3222 person-years; mean 6.3 years
  Jiang \[[@B12]\]                      Canada                   Liver                       1983--1998             2,034                 10,371 person-years
  Adami \[[@B6]\]                       Sweden                   Renal, liver, heart, lung   1970--1997             5,931                 40,360 person-years; mean 6.8 years
  Jensen \[[@B5]\]                      Denmark                  Renal, liver, heart, lung   1977--2006             5,279                 35,615 person-years; median 5 years
  Collett \[[@B4]\]                     United Kingdom           Renal, liver, heart, lung   1980--2007             37,617                Median 16 years
  Engels \[[@B19]\]                     United States            Renal, liver, heart, lung   1987--2008             175,732               775,147 person-years

^a^Denmark, Finland, Norway and Sweden.

Regional cancer registries were the main data source for identifying melanoma diagnoses. All studies reported rates of melanoma in transplant recipients compared to their respective age-, sex- and time-matched general population rates. One study also accounted for race \[[@B19]\].

Overall, transplant recipients have a pooled estimate of 2.4 times (95% confidence interval, 2.0 to 2.9) the risk of melanoma compared to the general population (Figure  [2](#F2){ref-type="fig"}). The overall I-squared was 46% (*P* = 0.04), indicating moderate heterogeneity between studies. Adjusting for the type of organ graft and the most recent year of transplant in the cohort reduced the I-squared value to 0%. Studies of renal or liver transplant recipients had an absolute increase in SIR of 0.29 compared to studies that included heart or lung transplant recipients (*P* = 0.01). Studies that included patients transplanted after the year 2000 had an increase in SIR of 0.41 compared to older studies (*P* = 0.03).
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Prognosis of post-transplant melanoma
-------------------------------------

Our search identified no population-based studies reporting data on outcomes of *de novo* melanoma arising post-transplantation. We identified ten retrospective, non-population-based cohort studies that compiled data from various sources \[[@B20]-[@B29]\]. As many of these papers present overlapping data, the most summative articles are described in Table  [2](#T2){ref-type="table"}.

###### 

**Non-population-based retrospective cohort studies reporting prognosis of patients with*de novo*post-transplant melanoma**

  **First author (publication year)**   **Location**     **Transplant data source**                  **Number of cases of melanoma**   **Staging data (number of patients with data)**   **Outcomes**
  ------------------------------------- ---------------- ------------------------------------------- --------------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Brewer \[[@B20]\]^a^                  United States    Mayo Clinic databases, OPTN, IPITTR         638                               AJCC pathologic stage (67 tumors)                 Worse 3-year, cause-specific survival for Breslow 1.51 to 3.0 mm and Clark level III or IV in transplant recipients versus controls.
                                                                                                                                       Breslow depth (123)                                
  Frankenthaler \[[@B21]\]              United States    BIDMC Cutaneous Oncology Program database   4 (renal transplant)              AJCC stage (19)                                   Similar relapse rates but worse overall survival in immunosuppressed group versus controls.
  15 (autoimmune disease)                                                                                                                                                                
                                                                                                                                                                                         Similar stage distribution at diagnosis compared to general melanoma database.
  Matin \[[@B26]\]                      Europe           SCOPE, AJCC                                 89                                Breslow depth (83)                                Worse overall survival for Breslow \>2 mm in transplant patients versus controls (HR 11.5, 95% CI 3.6 to 36.8), but not found for Breslow ≤2 mm (HR 1.5, 95% CI 0.31 to 6.9).
  Clark level (82)                                                                                                                                                                       
  Ulceration (79)                                                                                                                                                                        
                                                                                                                                                                                         14 patients with metastasis.
  Le Mire \[[@B22]\]                    United Kingdom   Oxford renal transplant unit                10                                Breslow depth (10)                                1 patient died from metastatic melanoma (Breslow 4.5 mm).
  Clark level (10)                                                                                                                                                                       
                                                                                                                                       Ulceration (10)                                   No recurrence in other cases (all \<1 mm).
  Veness \[[@B23]\]                     Australia        St Vincent Hospital, Sydney                 8                                 Regional lymph node status (2)                    4 deaths from metastasis.
  Lévêque \[[@B24]\]                    France           9 centers                                   17                                Breslow depth (16)                                4 deaths from metastasis
  Clark level (16)                                                                                                                                                                       
                                                                                                                                       Ulceration (16)                                    

^a^Overlap with three prior studies \[[@B25],[@B27],[@B28]\].

AJCC, American Joint Committee on Cancer; BIDMC, Beth Israel Deaconess Medical Center; CI, confidence interval; HR, hazard ratio; IPITTR, Israel Penn International Transplant Tumor Registry (previously Cincinnati transplant tumor registry); OPTN, Organ Procurement and Transplantation Network; SCOPE, Skin Care in Organ Transplant Patients, Europe.

In the largest study reporting on post-transplant melanoma outcomes, Brewer *et al*. retrospectively identified 638 cases of post-transplant melanoma in the United States collected from three Mayo Clinic databases (Florida, Rochester and Arizona), the Organ Procurement Transplant Network (OPTN) and the Israel Penn International Tumor Transplant Registry (IPITTR). They found that overall survival rates were worse in the transplant population compared to the general population based on Surveillance, Epidemiology and End Results (SEER) data. In particular, patients with melanomas with a Breslow depth of 1.51 to 3.00 mm and Clark levels III/IV had significantly worse outcomes compared with the expected survival rates in the general population \[[@B20]\]. A number of earlier publications also reported from these same databases \[[@B25],[@B27]-[@B29]\].

In the second largest non-overlapping study, Matin *et al.* reported worse outcomes for late stage (T3/T4) melanoma in transplant recipients compared to the general population \[[@B26]\]. This group analyzed cases from the Skin Care in Organ Transplant Patients, Europe network (SCOPE) database, which collects data from 14 transplant dermatology clinics. They compared 81 cases of melanoma in transplant patients to controls matched by age, sex, tumor thickness and ulceration, and found worse outcomes in transplant patients with stage T3/T4 tumors (\>2 mm thick). They found outcomes similar to the controls for early stage (T1/T2) melanomas. The hazard ratio for T3/T4 stage tumors was 11.49 (3.6 to 36.8).

Frankenthaler *et al*. reported on outcomes of 19 melanoma patients who were taking immunosuppressive therapies for renal transplantation (4 patients) or autoimmune conditions (15 patients). Each case was matched to three non-immunosuppressed controls with a similar age, sex, stage and location of primary tumor. They found no significant difference in relapse rates but worse overall survival in the immunosuppressed group, suggesting a more aggressive clinical course \[[@B21]\]. Other smaller, uncontrolled cohort studies have shown variable findings (Table  [2](#T2){ref-type="table"}).

Post-transplantation prognosis of pre-transplant melanoma
---------------------------------------------------------

Our search identified one population-based, retrospective, uncontrolled cohort study reporting on post-transplant outcomes of melanoma diagnosed prior to solid organ transplantation (Table  [3](#T3){ref-type="table"}) \[[@B30]\]. Chapman *et al.* reported data on cancers (excluding non-melanoma skin cancers) diagnosed before renal transplantation that subsequently recurred post-transplant. From the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), 19 of 11,894 patients who received renal transplants from 1963 to 1999 had a history of pre-transplant melanoma. Two of the nineteen patients (11%) had melanoma recurrence after transplant. No data on staging or post-transplant metastasis were available.

###### 

Uncontrolled cohort studies reporting post-transplant outcomes of melanoma diagnosed prior to solid organ transplantation

  **First author (publication year)**   **Population based**   **Location**             **Transplant data source**                               **Number of patients with pre-transplant melanoma**   **Staging data (number of patients with data)**   **Post-transplant outcomes (number of patients)**
  ------------------------------------- ---------------------- ------------------------ -------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------
  Chapman \[[@B30]\]                    Yes                    Australia, New Zealand   ANZDATA                                                  19                                                    Not available                                     Recurrence (2)
  Brewer \[[@B20]\]^a^                  No                     United States            Mayo Clinic databases, OPTN, IPITTR (1967--2007), SEER   59                                                    Breslow depth (15)                                Median post-melanoma follow-up of 10.5 years:
  Local recurrence (0)                                                                                                                                                                                                                                   
  Nodal metastasis (1)                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                         Lung metastasis (1)
  Matin \[[@B26]\]                      No                     Europe                   SCOPE network (14 clinics)                               9                                                     Breslow depth (6)                                 No deaths after median post-melanoma follow-up of 14 years

^a^Overlap with two prior studies \[[@B25],[@B28]\].

ANZDATA, Australian and New Zealand Dialysis and Transplant Registry; IPITTR, Israel Penn International Transplant Tumor Registry; OPTN, Organ Procurement and Transplantation Network; SCOPE, Skin Care in Organ transplant Patients, Europe; SEER, Surveillance, Epidemiology and End Results.

We also identified two non-population based, retrospective, uncontrolled cohort studies (Table  [3](#T3){ref-type="table"}) \[[@B20],[@B26]\]. Brewer *et al*. examined the post-transplant outcomes of 59 cases of pre-transplant melanoma collected from the IPITTR, OPTN and Mayo Clinic databases \[[@B20]\]. Breslow depth was available for a subset of 17 cases. They reported no recurrences and two melanoma metastases with a mean follow up of 10.5 years. This study encompassed data from two previous reports \[[@B25],[@B28]\], including data from IPITTR that originally suggested that 6 of 31 patients with pre-transplant melanoma died from post-transplant recurrences \[[@B28]\]. However, these findings could not be replicated by Brewer *et al*., whose study excluded melanoma diagnoses from IPITTR that were not histopathologically confirmed (personal communication, J Brewer, MD, 24 February 2012).

Matin *et al*. reported data voluntarily provided by physicians in the SCOPE network database (Table  [3](#T3){ref-type="table"}). Breslow depth was available for six of nine patients with pre-transplant melanoma. No post-transplant deaths were noted after 3.3 to 42 years of post-melanoma follow-up (median 14 years) and 0.5 to 10.2 years of post-transplant follow-up (median 5 years) \[[@B26]\].

Discussion
==========

This is the first systematic review of melanoma incidence and outcomes in the solid organ transplant population. Compared to the general population, there is a 2.4-fold increased incidence of melanoma in the transplant population. No population-based outcome data were identified for melanoma arising post-transplant. Data from non-population-based cohort studies suggest a worse prognosis for late-stage melanoma developing in a transplant population versus a general population. For melanoma arising prior to transplantation, one uncontrolled population-based study found an 11% local recurrence rate post-transplant, although staging and survival data were lacking.

Immune function plays a prominent role in the biological response to melanoma \[[@B31]\]. The increased incidence of melanoma in the transplant population is likely due to decreased immune surveillance, although the oncogenic potential of systemic immunosuppressant medications may also play a role. Reduced immune surveillance may also lead to poorer outcomes in melanoma arising pre- and post-transplant, but clinical data are limited. Late transmission of donor melanoma after up to 32 years of melanoma-free survival in the host suggests that immunosuppression can promote activation of previously dormant melanoma cells \[[@B32]\]. Melanoma regression with removal of immunosuppression has also been described \[[@B33]\], and many of the systemic treatments for metastatic melanoma are immune-activating therapies \[[@B34]\].

In transplant candidates with a history of melanoma, the risk of post-transplant recurrence and metastasis has important implications for the decision to pursue transplantation. The quality of data available to guide this decision is currently limited to uncontrolled, non-population-based reports that lack staging information. Otley *et al*. proposed a consensus-based framework of waiting time prior to consideration of transplantation, based on melanoma stage \[[@B35]\]. The risks and benefits of pursuing transplantation versus continued dialysis or organ failure in patients with a history of melanoma need to be weighed on a case-by-case basis.

Our study has several limitations. Firstly, our review is limited by the quality of the included studies. Only one incidence study adjusted the melanoma rates for race, an important risk factor for skin cancer \[[@B19]\]. This could affect the estimates of relative risk if the racial composition differed between transplant and general populations. Data on the level of immunosuppression were also not available for the identified studies, with inevitable heterogeneity of medications and dosing within each transplant population and between studies. Furthermore, staging information was uniformly lacking, which precluded evaluation of the severity of melanoma at the time of diagnosis in the transplant population versus the general population, and the impact of stage on melanoma outcomes. Finally, the overall heterogeneity of the included incidence studies was moderate, as reflected by the I-squared value of 46%. We explored two potential sources of heterogeneity and found that the graft type and cohort year accounted for all of the between-study variability.

Conclusion
==========

Our systematic review found that there is a 2.4-fold increased incidence of melanoma in the transplant population compared to the general population. Non-population-based data suggest a worse prognosis for late-stage melanoma developing in the transplant population versus the general population. These findings have several implications for clinical practice and research. The significantly increased overall risk of melanoma arising post-transplant means that these patients warrant a multi-pronged approach to primary and secondary prevention, including regular full skin examinations for cancer screening, a low biopsy threshold for suspicious pigmented lesions, and continual education on the importance of sun avoidance and protection. Our study has also identified an important knowledge gap that should be addressed in future research. Population-based studies that account for melanoma stage and risk factors are needed for patients and clinicians to understand better the prognosis of pre- and post-transplant melanoma. These data would help to inform treatment decisions, as tumors known to have a poorer prognosis may require more aggressive management, including significant reduction or discontinuation of immunosuppression. Robust outcome and staging data would also help to inform the decision to pursue, avoid or delay transplantation in patients with a history of melanoma.
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